Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
SEATTLE, Aug. 25, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at two upcoming conferences in September. Presenting at the conferences will be Brad Gray, Chief Executive Officer.
Brad Gray, President and Chief Executive Officer, is scheduled to present at the Baird 2016 Global Healthcare Conference in New York, NY on Wednesday, September 7, 2016 at 12:45pm PT (3:45pm ET).
Mr. Gray is also scheduled to present at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2016 at 6:55am PT (9:55am ET).
Interested parties can access a live webcast of both presentations on the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentations and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
